Tumor suppressor protein p53 aggregates in the hypoxic core of solid tumors. C terminus of Hsc70-interacting protein (CHIP) displays chaperone as well as E3 ligase activities in both stabilizing and degrading wild-type and mutant p53. In this study, we have discovered that CHIP selectively degrades aggregating mutant p53 under both normal and hypoxic conditions. Silencing of CHIP alleviates degradation of aggregating mutant p53 in both normoxia and hypoxia, but has no significant effect on the level of nonaggregating mutant p53. Although both U-box and TPR domains of CHIP are responsible for p53 degradation, the U-box domain selectively binds to aggregating mutant p53, whereas the TPR domain interacts with nonaggregating mutant p53. The degradation of mutant p53 by CHIP is shown to be via autophagy through K63-linked polyubiquitination. Both in normoxia and under physiological hypoxia, the level of aggregating mutant p53 in the presence of CHIP was reduced threefold, whereas under serum starvation, it was reduced fivefold. Interestingly, both wild-type and mutant p53 interact with and stabilize CHIP at the post-translational level, suggesting a chaperone synergy between p53 and CHIP. This finding may have strong therapeutic significance via selective degradation of oncogenic mutant p53 in regressing hypoxic tumors.
Introduction
p53 is one of the most frequently mutated proteins in human cancer. Some of these mutations may result in dominant phenotypes, also described as oncogenic gain of function. Such phenotypes actively contribute to cancer development and progression [1, 2] . These include drug resistance, pro-proliferative anti-apoptotic functions, increased cell migration, invasion and angiogenesis [3] [4] [5] . At high expression levels, oncogenic mutant p53 may acquire a misfolded and partially denatured conformation, generating micro-and macroaggregates that can coaggregate with both wildtype p53 and its family members p63 and p73, rendering them inactive through a possible prion effect [6, 7] . We have previously shown that, wild-type p53 acquires a mutant conformation in the hypoxic core of MCF-7 solid tumors, and its conformation is oxygen dependent [8] . Both p53's chaperone function and a re-oxygenation event were used to rescue mutant p53 in cancer cells at the transcription and proteome levels in regressing breast tumor in mice xenograft. The oxygen-mediated rescue of mutant p53 followed by its trans-activation was shown to be responsible for the induction of p53-downstream apoptotic, cell cycle arrest and DNA-repair genes [8] . p53 mutants can be of two types: structural and contact. Structural mutant p53 displays both dominant loss of function and gain of function consequences, which are a direct result of increased aggregation propensity [6] . Survival of patients carrying contact mutations of p53 is significantly higher than carriers of aggregating mutant p53
Abbreviations CHIP, C terminus of Hsc70-interacting protein; HIF1A, hypoxia-inducible factor 1A; MDM2, murine double minute 2; Ni-NTA, Nickelnitrilotriacetic acid; PI, propidium iodide; TPR, tetratricopeptide repeat; Ub, ubiquitin; UPS, ubiquitin-proteasome system. [9, 10] . As different mutant p53 alleles may exhibit certain unique characteristics and interact with a wide range of different proteins [1] , multiple mechanisms might be involved in accumulation of mutant p53 protein. Therefore, targeting mutant p53 for protein degradation, rather than its reactivation, might be another strategy for drug development for hypoxic tumors.
p53 is maintained at a low level by continuous degradation via proteasomes through E3 ubiquitin ligase [11, 12] . Other E3 ligases, including p300 [13] , Pirh2 [14] , COP1 [15] and C terminus of Hsc70-interacting protein (CHIP) [16] , are also responsible for p53 degradation. Unlike wild-type p53, which is degraded by the ubiquitin-proteasome system (UPS), D133 p53a, an inhibitor of full-length p53 function, is degraded via autophagy during replicative senescence [17] . Autophagy inhibition under cellular stress has been shown to induce the degradation of mutant p53 via chaperone-mediated autophagy [18] . Glucose starvation also induces mutant p53 protein degradation through autophagy, which renders tumor cells hypersensitive to autophagic cell death [19] . Besides, Zn(II)-curcumin displays a novel mechanism in the degradation of mutant p53, involving induction of mutant p53 degradation via wild-type p53-mediated autophagy [20] . However, the molecular mechanisms and cellular players involved in autophagic degradation of mutant p53 are still unknown.
When tumor cells are exposed to hypoxic conditions, murine double minute 2 (MDM2) activity is compromised due to interaction with hypoxia-inducible factor 1A (HIF1A) [21] . However, CHIP was shown to degrade p53 in hypoxia-induced heart with myocardial infarction [22] by an unknown mechanism. CHIP is an E3 ligase that is known to ubiquitinate and degrade its substrate proteins via both proteasomal [23, 24] and lysosomal pathways [25] . In addition, CHIP has been shown to be important for mutant p53 degradation [16, [26] [27] [28] . The accumulation of mutant p53 in hypoxia raises the question of whether CHIP could degrade p53 mutants in hypoxia. In this study, we have used aggregation-prone p53 mutants R110L, R110P and R175H and folded or nonaggregating p53 mutants R248W and R273H. We have discovered a new role of CHIP in degrading mutant p53 via the lysosome-dependent pathway. CHIP preferentially degrades aggregating mutant p53 and wild-type p53 through K63 and K48 polyubiquitinition chains, respectively. CHIP utilizes both tetratricopeptide repeat (TPR) and U-box domains for promoting degradation of mutant p53. During p53 inactivation under stress, a parallel autophagic degradation of mutant p53 by CHIP that is stabilized by p53 suggests a feedback mechanism that is necessary for maintaining cell homeostasis. This study may open up a new therapeutic window for reducing the load of mutant p53 in tumor cells.
Results

CHIP mediates degradation of aggregating mutant p53 in hypoxia and serum stress conditions
Hypoxia is a characteristic feature of the tumor microenvironment and plays a major role in tumor progression and invasion. Furthermore, hypoxia selects cells with oncogenic mutant p53 over cells harboring wild-type p53 by inducing apoptosis-mediated death of the latter. While the ability of MDM2 to degrade p53 is compromised in hypoxia, CHIP is reported to degrade wild-type p53 in such condition [22] . Therefore, it was pertinent to investigate whether CHIP is able to degrade mutant p53 in hypoxia. Degradation of wild-type p53 by CHIP in hypoxia was taken as a positive control for this study. We expressed wild-type p53 or mutant p53 in HCT116 p53 (À/À) cells in the absence or presence of CHIP. Following this, cells were incubated in normoxia, 0.1% hypoxia or 1% hypoxia as compared to control (without CHIP). p53 levels were estimated by western blotting. On analysis of the results, it was observed that the degradation of wild-type p53 by CHIP was approximately twofold in normoxia, 1% hypoxia and 0.1% hypoxia as compared to control (without CHIP) (Fig. 1A , lanes 2, 4 and 6, respectively). CHIP showed around threefold degradation of both the aggregating p53 mutants (R110P and R175H) in normoxia (Fig. 1B , lanes 2 and 8) and 1% hypoxia (Fig. 1B, lanes 4 and 10) and around 2.5-fold degradation in 0.1% hypoxia as compared to control (without CHIP) (Fig. 1B, lanes 6 and  11) . No significant CHIP-mediated degradation of either of the two nonaggregating p53 mutants was observed in normoxia or hypoxia (Fig. 1C) . The effect of CHIP knockdown on endogenous wild-type and mutant p53 was studied in HCT116 p53 (+/+) ( Fig. 2A), CAL33 (Fig. 2B ) and A431 (Fig. 2C) cells. It was observed that CHIP knockdown resulted in an elevated protein level for wild-type p53 (in HCT116) and R175H p53 (in CAL33) in both hypoxia and 0.1% hypoxia. However, protein level of R273H p53 was not significantly affected by knockdown of CHIP in either normoxia or hypoxia. Following this, the half-life of R175H p53 in CAL33 cells in the presence and absence of CHIP was studied in both normoxia (Fig. 2D ) and 0.1% hypoxia (Fig. 2E) . The half-life of p53 was found to decrease in the presence of CHIP in both normoxia and hypoxia. Real-time PCR was also carried out to confirm that CHIP-mediated destabilization of aggregating mutant p53 was at the post-translational level and not at the transcriptional level (Fig. 2F,G) . Analysis of the results showed that CHIP did not affect the p53 mRNA level. Together, this set of results establishes that CHIP negatively regulates the stability of wild-type p53 and aggregating mutant p53 in normoxia and hypoxia. However, it is unable to degrade nonaggregating mutant p53 in either normoxia or hypoxia.
It is known that wild-type p53 is degraded via the UPS [16] , whereas mutant p53 has been reported to be degraded by the autophagic degradation pathway [18, 19] . Several studies report that CHIP can degrade substrate proteins via the UPS [16, 29] . Recent reports also suggest that CHIP can degrade substrates such as HIF1A [25, 30] and a-synuclein [31] through autophagic pathway. It can thus be concluded from these studies that CHIP is capable of degrading its substrate proteins via both the UPS and autophagy. To understand whether autophagy plays a role in the degradation of aggregating p53 mutants by CHIP, serum starvation was used to induce autophagy. Starvation is known to induce an autophagic response in cells to preserve resources [32, 33] . It also results in oxidative stress that in turn leads to an autophagic response [34] . Autophagy induction was confirmed by studying the localization of LC3 following serum starvation. HCT116 p53 (À/À) cells were transfected with GFP-LC3 and cultured in the presence or absence of serum starvation. Localization of GFP-LC3 was found to be enhanced in cytoplasmic puncta in the case of serum starvation, indicating enhanced autophagy (Fig. 3A) . To study effect of autophagy induction on wild-type and mutant p53 degradation, HCT116 p53 (À/À) cells were transfected with wildtype p53 or mutant p53 in the presence or absence of CHIP. Serum starvation of the cells did not significantly affect CHIP-mediated degradation of wild-type p53 (Fig. 3B, lanes 2 and 4) . On the other hand, while an approximately 2.5-fold CHIP-mediated degradation of both the aggregating p53 mutants (R110P and R175H) was observed in normal culture condition (Fig. 3C, lanes 2 and 6) , about fivefold degradation was observed in serum starved condition (Fig. 3C , lanes 4 and 8) as compared to control (without CHIP). No significant degradation of mutant p53 was observed in serum starved or normal culture conditions (Fig. 3D) . These results show that serum starvation specifically enhances the CHIPmediated degradation of aggregating p53 mutants while not significantly affecting the degradation of wild-type p53 by CHIP. These findings altogether suggest that autophagy might play a role in CHIPmediated degradation of aggregating mutant p53. Fig. 1 . CHIP degrades wild-type p53 and aggregating mutant p53 in hypoxic conditions. HCT116 p53 (À/À) cells were transfected with wildtype (wt) p53 (A), aggregating p53 mutants R110P or R175H (B), or nonaggregating p53 mutants R248W or R273H (C) along with empty plasmid pcDNA3.1 or CHIP. Following 24 h of transfection, cells were incubated in normoxia, 1% hypoxia or 0.1% hypoxia for 24 h. Degradation of wild-type or mutant p53 on coexpression with CHIP was analyzed by western blotting. b-Actin was used as a loading control. p53 expression was quantitated using IMAGEJ software. Data were expressed as mean AE SE from three different experiments. Statistical analysis was performed by one-way ANOVA with the level of significance at *P ≤ 0.05 or **P < 0.01.
CHIP selectively degrades aggregating mutant p53 via autophagy
Having established that serum starvation enhances CHIP-mediated degradation of aggregating mutant p53, we were interested to study the pathway involved. There are two degradation pathways in a cell: the UPS and autophagy. To confirm which of these pathways CHIP employs to degrade aggregating mutant p53, the proteolytic activity of the 26S proteasome and lysosome was selectively inhibited. Chloroquine was used as an inhibitor of autophagy as it is known to raise the pH of lysosomes, thus inhibiting the activity of lysosomal enzymes. MG132, which inhibits the chymotrypsin-like site of the b-subunit of the 20S proteosome, was used as a proteasome inhibitor. Two p53-null cell lines (HCT116 and H1299) were used to transiently express wild-type or mutant p53 along with or in the absence of wild-type CHIP. On analysis of western blot results, CHIPmediated degradation of wild-type p53 was found to be unaffected by chloroquine treatment in both the cell lines level was also carried out for cells treated as above. Normalization was carried out with b-actin. Data were expressed as mean AE SE from three-independent experiments. Statistical analysis was performed by two-tailed Student's t test or one-way ANOVA wherever applicable, with the level of significance at **P ≤ 0.01.
( Fig. 4A ,F lane 3) but was inhibited on treatment with MG132 ( Fig. 4F lane 4) . On the other hand, the degradation of aggregating p53 mutants R110P and R175H by CHIP was inhibited in the presence of chloroquine in both the cell lines, but remained unaffected on MG132 treatment (Fig. 4B ,C,G). Protein level of nonaggregating mutant p53 coexpressed with CHIP was not significantly altered in the presence or absence of either of the two inhibitors ( Fig. 4D ,E,H). Next, the CAL33 cell line was used to study the mode of degradation of endogenous R175H p53 in normoxia and 0.1% hypoxia. CAL33 cells were transfected with empty plasmid or wild-type CHIP and cultured in normoxia (Fig. 5A ) or hypoxia (Fig. 5B ). Treatment with chloroquine or MG132 was carried out before harvesting the cells. On analysis of the results, CHIP-mediated degradation of endogenous R175H p53 was found to be autophagy dependent in both normoxia and hypoxia. These results together demonstrate that lysosome inhibition rescues aggregating p53 mutants from CHIP-mediated destabilization, thus establishing that CHIP degrades aggregating mutant p53 via the lysosome-mediated autophagic degradation pathway.
Both TPR and U-box domains of CHIP control p53 degradation
After studying CHIP-mediated lysosomal degradation of aggregating mutant p53, the physical interaction of CHIP with wild-type and mutant p53 was examined. CHIP is functionally divided into three domains: the Nterminal TPR domain with which it associates with chaperones, a central charged domain and a C-terminal U-box domain responsible for the E3 ligase activity. To identify the domain of CHIP involved in its association with wild-type and mutant p53, CHIP deletion mutants were used. A CHIP DTPR mutant lacked the TPR domain and thus chaperone binding ability, and a CHIP DUbox mutant was deficient in the U-box domain and thus in E3-ligase activity. HCT116 p53 (À/À) cells were cotransfected with myc-CHIP or its deletion mutants and wild-type, aggregating (R110P, R175H) or nonaggregating (R248W, R273H) p53 mutants ( Fig. 6A,B) .
Results of a co-immunoprecipitation assay showed that both wild-type and aggregating p53 mutants (R110P and R175H) co-immunoprecipitated with CHIP and the CHIP DTPR mutant. However, deletion of the U-box domain in the CHIP DUbox mutant strongly reduced the amount of p53 co-immunoprecipitated with CHIP ( Fig. 6A ). On the contrary, nonaggregating p53 mutants (R248W and R273H) co-immunoprecipitated with CHIP and the CHIP DUbox mutant (Fig. 6B ). Similar results were obtained when endogenous R175H p53 mutant in the CAL33 cell line (Fig. 6C ) and R273H p53 mutant in the A431 cell line (Fig. 6D) were studied for the domain of CHIP essential for their interaction with CHIP. These findings indicate that wild-type and aggregating mutant p53 interact with the U-box domain of CHIP, whereas the U-box domain might not be essential for interaction of nonaggregating mutant p53 with CHIP. For identification of the domain of CHIP principally involved in the degradation of wild-type and aggregating mutant p53, CHIP point mutants (CHIP K30A and CHIP H260Q ) and deletion mutants (CHIP DTPR and CHIP DUbox ) were studied for their ability to degrade wild-type and mutant p53. CHIP K30A has a substitution mutation in the TPR domain that abolished its ability to associate with chaperones. CHIP H260Q has a substitution mutation in the U-box domain and abrogated E3 ligase activity. HCT116 p53 (À/À) cells were transfected with p53 (wild-type/mutant) in the absence or presence of CHIP or its mutants. On analysis of western blot results, it was observed that CHIPmediated degradation of wild-type p53 was compromised when either of the domains of CHIP was mutated via deletion or point mutation (Fig. 7A,  D) . Similarly, the degradation of aggregating p53 mutants (R110P and R175H) is compromised on mutation of either of the domains of CHIP (Fig. 7B,  E) . However, neither CHIP nor any of its mutants carry out a significant degradation of nonaggregating mutant p53 (Fig. 7C,F) . Altogether, these results indicate that both TPR and U-box domains of CHIP are essential for the degradation of wild-type p53 and aggregating mutant p53.
Differential ubiquitination pattern dictates CHIPmediated autophagic degradation of p53
After studying CHIP-mediated degradation of aggregating p53 mutants, it was vital to investigate whether this process is ubiquitination dependent. CHIP is an E3 ligase with many known substrates. It polyubiquitinates these substrates for their subsequent proteasomal or lysosomal degradation, for example, p53 [16] , HIF1A [25] , hTERT [35] and PTEN [36] . To confirm whether CHIP ubiquitinates aggregating mutant p53, an in vivo ubiquitination assay was performed for these mutants in the presence of CHIP. As CHIP is known to ubiquitinate wild-type p53 for its degradation, it was used as a positive control. HCT116 p53 (À/À) cells were transfected with p53 (wild-type/ mutant) and His-ubiquitin (His-Ub) in the presence or absence of wild-type CHIP. Cells were treated with chloroquine or MG132 to inhibit the degradation of ubiquitinated p53. Western blot results show that high molecular mass ubiquitinated forms of wild-type p53 are enhanced on coexpression with CHIP when the proteasome is inhibited (Fig. 8A, lane 4) . On the other hand, high molecular mass ubiquitinated forms of aggregating p53 mutants R110P and R175H are enhanced on coexpression with CHIP in the presence of lysosomal inhibition (Fig. 8B, lane 2 and 6) . No appreciable ubiquitination of nonaggregating mutant p53 was observed in the presence of either lysosomal or proteasomal inhibitors (Fig. 8C) . Collectively, these results suggest that CHIP ubiquitinates and degrades aggregating mutant p53 via the lysosomal pathway. Nonaggregating mutant p53 is not ubiquitinated or degraded by CHIP.
Substrates can be linked with different polyubiquitin chains using the seven unique lysine residues in ubiquitin, that is, 6, 11, 48, 63, etc. These polyubiquitin chains are specifically recognized by different proteins involved in the substrate degradation [37] . It has been established that substrates are conjugated with K48-linked polyubiquitin chains for degradation in proteasomes [38, 39] . K63-linked polyubiquitin chains have been reported to target a substrate protein for lysosomal degradation [40] [41] [42] . In addition, CHIP is reported to be capable of conjugating substrate proteins with K63-linked polyubiquitin chains [30, 43] . It was thus of interest to address whether aggregating p53 mutants are tagged with K63-linked polyubiquitin chains by CHIP for their lysosomal degradation. Ubiquitin mutants with replacement of either the 48th or 63rd lysine residue with an arginine were used to specifically inhibit the formation of K48-or K63-linked polyubiquitin chains. An in vivo ubiquitination assay was performed using the abovementioned point mutants of ubiquitin. Wild-type p53 is known to be tagged with K48-linked polyubiquitin chains [44] and was therefore used as a positive control , aggregating mutants of p53 (R110P and R175H) (E), or nonaggregating mutants of p53 (R248W and R273H) (F) along with empty plasmid pcDNA3.1, wild-type CHIP, or its point mutants. Degradation of wild-type or mutant p53 on coexpression with CHIP or its mutants was analyzed by western blotting. b-Actin was used as a loading control. p53 expression was quantitated using IMAGEJ software. Data were expressed as mean AE SE from three different experiments. Statistical analysis was performed by one-way ANOVA with the level of significance at *P ≤ 0.05 or **P < 0.01.
for this study. HCT116 p53 (À/À) cells were transfected with His-Ub (wild-type, K48R or K63R) and p53 (wild-type/mutant) in the presence or absence of CHIP. After western blotting, no appreciable ubiquitination of wild-type p53 was seen even in the presence of CHIP when transfected with K48R Ub (Fig. 8D, lane 3) , whereas polyubiquitinated forms of wild-type p53 were observed in the presence of CHIP when transfected with wild-type Ub (Fig. 5D, lanes 2 and 4) or K63R Ub (Fig. 8D, lane 4) . On the contrary, polyubiquitinated forms of aggregating p53 mutants R110P and R175H were observed in the presence of CHIP when transfected with wild-type Ub (Fig. 8E , lanes 2 and 6) and K48R Ub (Fig. 8E, lanes 3 and 7) . However, no appreciable ubiquitination of mutant p53 was seen even in the presence of CHIP when transfected with K63R Ub (Fig. 8E, lane 4 and 8) . These results show that CHIP catalyzes attachment of K48-linked polyubiquitin chains to wild-type p53 and K63-linked polyubiquitin chains to aggregating p53 mutants for their degradation. This finding is in accordance with a recent report showing that CHIP attaches K63-linked polyubiquitin chains to HIF1A for its autophagic degradation [30] . Transfected cells were treated with either lysosome (chloroquine) or proteosome (MG132) inhibitors to inhibit the degradation of ubiquitinated p53. Following treatment, cells were lysed and washed in denaturing conditions to inactivate the deubiquitinating enzymes. Proteins covalently linked with His-Ub were precipitated from cell lysate using Nickel-nitrilotriacetic acid (Ni-NTA) beads. Western blotting was carried out with anti-p53 antibodies to detect ubiquitinated p53. (D,E) K63 ubiquitin-linked chains are necessary for lysosomal degradation of aggregating p53 mutants. Wild-type p53 (D) or aggregating p53 mutants R110P and R175H (E) were transfected in the presence or absence of CHIP along with His-wt Ub, His-K48R Ub or His-K63R Ub. Cells transfected with wild-type p53 and aggregating p53 mutants were treated with MG132 and chloroquine, respectively, to inhibit the degradation of ubiquitinated p53. Ubiquitinated p53 was precipitated from whole-cell lysate using Ni-NTA beads, followed by western blotting with anti-p53 antibody.
p53 stabilizes CHIP at the post-translational level p53 is known to regulate various genes involved in apoptosis, cell cycle arrest and maintenance of genetic integrity. In addition, p53 also regulates the expression of a number of its ligases including MDM2 [11, 12] , Pirh2 [14] and COP1 [15] . Mutant p53 is also known to regulate many genes involved in oncogenic pathways [45, 46] . It was thus of interest to investigate whether wild-type and mutant p53 regulate CHIP. To examine whether wild-type and mutant p53 affect CHIP protein expression, first we studied the effect of stress-dependent induction of endogenous p53 on CHIP. The expression of p53 was induced by the treatment of cells with physiological stresses including serum starvation and genotoxic stress (Fig. 9A-D) . HEK293 and A549 cell lines, both of which express wild-type p53, were utilized for this study. Western blotting was performed to study protein levels of p53 and CHIP. Analysis of western blot results revealed that a stress-induced increase in p53 protein expression was synchronized with an increase in CHIP level in both HEK 293 and A549 cell lines. It was observed that stress-induced p53 overexpression was accompanied by an increase in CHIP protein level. Once the effect of upregulation of endogenous p53 on CHIP was established, the effect of exogenous overexpression of wild-type and mutant p53 was studied. To achieve this, wild-type p53 (Fig. 6E, lane 2) , aggregating p53 mutants R110L, R110P and R175H (Fig. 9E, lanes 3 , 4, and 5), and nonaggregating p53 mutants R248W and R273H (Fig. 9E, lanes 6 and 7) were transiently expressed in HCT116 (p53À/À) cells. On analysis of the western blot results, it was observed that transient overexpression of wild-type p53 as well as aggregating and nonaggregating mutant p53 resulted in an increased protein level of CHIP. These results indicate that CHIP protein level is regulated by both wild-type and mutant p53.
Having shown upregulation of CHIP protein levels by both wild-type and mutant p53, whether wild-type and mutant p53 also regulate CHIP at the transcriptional level was investigated. For this purpose, CHIP mRNAs were quantitated and compared in HCT116 p53 (À/À) and HCT116 p53 (+/+) cells by real-time PCR. The result showed that the CHIP mRNA levels were not significantly different in the two cell lines irrespective of the p53 status. p21 (which was used as a positive control for transcription regulation by p53) mRNA levels, on the other hand, were found to be approximately five times higher in HCT116 p53 (+/+) cells as compared with HCT116 p53 (À/À) cells (Fig. 9F) . Next, the effect of exogenous overexpression of wild-type and mutant p53 on transcription of the CHIP gene was studied. Aggregating mutants (R110L p53, R110P p53, R175H p53) and nonaggregating mutants (R248W p53, R273H p53) were used in this experiment. HCT116 p53 (À/À) cells were transfected with empty plasmid pcDNA3.1, wild-type p53 or mutant p53. On analysis of qPCR results, it was observed that overexpression of either wild-type or mutant p53 did not significantly alter the CHIP mRNA levels. However, p21 mRNA level was found to increase by approximately threefold on wild-type p53 transfection, but was not significantly altered on ectopic expression of any of the p53 mutants (Fig. 9G) . Next, effect of hypoxic upregulation of wild-type and mutant p53 on the CHIP mRNA levels was studied by culturing HCT116 p53 (+/+), CAL33 and A431 cells in normoxia or 0.1% hypoxia (Fig. 9H) . Analysis of the results showed that the CHIP mRNA level was not significantly altered in any of the cell lines in the presence of hypoxia. These results suggest that while wild-type and mutant p53 regulate CHIP at the protein level, this regulation is not exerted at the level of gene transcription. An immunoprecipitation assay of CHIP with wild-type and mutant p53 showed that CHIP interacts with wild-type p53, aggregating p53 mutants (R110P and R175H) and nonaggregating p53 mutants (R248W and R273H) (Fig. 6 ). This result correlates with an earlier finding of our group that showed that CHIP is able to bind with both native (Ab-1620) and misfolded (Ab-240) forms of p53 [47] . Also, yet another study from our group established that p53 is capable of acting as a chaperone [48] . These results together suggest that p53 is capable of physically binding with CHIP and stabilizing it.
CHIP-mediated degradation of mutant p53 increases cell death in hypoxia
Finally, we assessed the biological relevance of CHIPmediated autophagic degradation of aggregating mutant p53 in hypoxia. For this purpose, CAL33 cells harboring endogenous R175H p53 mutant were transfected with empty plasmid or wtCHIP. Cells were later incubated in normoxia or 0.1% hypoxia. Cell death was studied using propidium iodide (PI) stain, which is taken up only by dead cells. On studying PI fluorescence intensity by flow cytometry, it was observed that cell death in hypoxia was enhanced in cells transfected with CHIP as compared with cells transfected with empty vector (Fig. 10A ). HCT116 p53 (+/+) cells that were similarly treated and taken as a control showed an opposite result. Cell death was decreased in cells transfected with wtCHIP as compared with pcDNA 3.1 (Fig. 10B ). This may be attributed to R175H p53 entrapping p53 family proteins p63 and p73, thus rendering them nonfunctional [6, 7] . Degradation of R175H p53 by CHIP frees p63 and p73, allowing them to restore hypoxia-mediated cell death.
Discussion
In hypoxic tumors inhibition of apoptosis is caused by accumulation of mutant p53 that might undergo irreversible aggregation. There is a selection of cells . (E) Exogenous expression of wild-type and mutant p53 leads to an increase in CHIP protein level. HCT116 p53 (À/À) cells were transfected with empty vector pcDNA3.1, wild-type p53 or mutant p53 (R110L, R110P, R175H, R248W and R273H). p53 and CHIP protein levels were estimated by western blotting. b-Actin was used as a loading control. (F) CHIP mRNA level is independent of p53 status in HCT116 cells. Total RNA was extracted from HCT116 p53 (À/À) and HCT116 p53 (+/+) cells. cDNA was synthesized and real-time PCR was performed to calculate CHIP and p21 transcript levels. (G) CHIP mRNA level is not affected by exogenous overexpression of wild-type and mutant p53. HCT116 p53 (À/À) cells were transfected with empty plasmid pcDNA3.1, wild-type p53 or mutant p53. Total RNA was extracted and cDNA was synthesized. Real-time PCR was performed to calculate CHIP and p21 transcript levels. (H) CHIP mRNA level is not affected by hypoxic upregulation of p53. HCT116 p53 (+/+), CAL33 and A431 cells were cultured in normoxia or 0.1% hypoxia for 24 h. Total RNA was extracted and cDNA was synthesized. Real-time PCR was performed to calculate CHIP transcript levels. Normalization was carried out with b-actin. Data were expressed as mean AE SE from threeindependent experiments. Statistical analysis was performed by two-tailed Student's t test or one-way ANOVA wherever applicable, with the level of significance at *P ≤ 0.05, **P ≤ 0.01.
harboring mutant p53 over those with wild-type p53 as the latter undergo hypoxia-induced apoptotic death while the former survive [49] . Cancer patients harboring aggregating mutant p53 have a poorer prognosis than patients harboring nonaggregating mutant p53 [6] . Proteins forming micro-and macroaggregates are degraded via the autophagic pathway because of their larger size rendering them resistant to proteasomal degradation [50, 51] . Therefore, the ability of CHIP to specifically target aggregating mutant p53 for degradation in hypoxia may have potential for hypoxic tumor regression. CHIP has been shown to degrade wild-type p53 via the UPS [16] . However, autophagy is reported to play a role in degradation of mutant p53 [18, 19] as well as p53 isoform D133 p53a [17] . Besides, Zn(II)-curcumin also degrades mutant p53 via wild-type p53-mediated autophagy [20] . In this study, we have demonstrated that CHIP could differentially degrade aggregating mutant p53 (R110P, R175H) over nonaggregating mutant p53 (R248W, R273H). Cells in a solid tumor are exposed to varying degrees of hypoxia in which MDM2 fails to degrade p53 [21] . Both under hypoxia and under serum starvation, CHIP was able to degrade p53 aggregating mutants R110P and R175H. CHIP was earlier shown to degrade wild-type p53 under hypoxic conditions in ischemic heart cells [22] .
CHIP is reported to have a tumor suppressor function in renal [52] , gastric [53, 54] , colorectal [55] and breast cancers [56, 57] with an unknown mechanism. We had earlier shown that CHIP is able to restore wild-type function to mutant p53 thus causing hypoxic tumor regression [48] . CHIP-mediated autophagic degradation of aggregating mutant p53 via E3 ligase activity may explain its tumor suppressor function in preventing carcinogenesis. Our results show that the U-box domain of CHIP is essential for its interaction with aggregating mutant p53, whereas both TPR and U-box domains are required for CHIP-mediated degradation of aggregating mutant p53. This indicates that both E3 ligase activity of CHIP and its interaction with Hsp70 may be essential for degradation of aggregating mutant p53. This is in accordance with earlier reports that interaction of CHIP with HSP70 and HSP90 plays an important role in substrate recognition and degradation by CHIP [58, 59] . A similar result was reported by us earlier with regard to CHIPmediated degradation of b-site APP-cleaving enzyme 1 [29] . Similarly, the U-box domain was shown to be involved in interaction with interferon regulatory factor-1 (IRF1) with no role of chaperones in this interaction [60] . On the contrary, the TPR domain was essential for interaction of CHIP with a-synuclein [31] and RunX1, a member of the Runt transcription factor family [61] .
CHIP-mediated autophagic degradation of aggregating mutant p53 is ubiquitination dependent, which is similar to CHIP-mediated autophagic degradation of HIF1A [25] . Differential ubiquitination of aggregating and nonaggregating mutant p53 by CHIP may be explained by the difference in interaction of CHIP with these p53 mutants. The U-box domain is essential for interaction of CHIP with aggregating mutant p53, but not nonaggregating mutant p53. Ubiquitin possesses seven lysine residues, K6, K11, K27, K29, K33, K48 and K63, each of which may be utilized for the formation of polyubiquitin chains. K48-and K63-linked polyubiquitin chains have been shown to be essential for the degradation of substrate proteins in 26S proteasomes and lysosomes, respectively [51] . CHIP is reported to catalyze the formation of both K48 and K63 polyubiquitin chains [43] . Our results confirm that CHIP tags aggregating mutant p53 with K63-linked polyubiquitin chains prior to their lysosomal degradation, as is the case with HIF1A [30] . Furthermore, in cells a CHIP-p53 synergy loop seems to exist as both wild-type and mutant p53 regulate CHIP level as a post-translational event, as overexpression of wild-type or mutant p53 results in an increase in CHIP protein level. In addition, we have shown that CHIP interacts with wild-type p53, as well as with aggregating and nonaggregating mutant p53. This is in accordance with one of our previous studies where we showed that CHIP is capable of binding to both Ab-1620 (wild-type) and Ab-240 (mutant) forms of p53 [47] . Stabilization of CHIP by p53 could be due to p53's chaperone function [48] . We have shown that CHIP is able to induce cell death in cells harboring endogenous R175H p53 in the presence of hypoxia. This finding is supported by an earlier study that reported that autophagic degradation of R175H p53 mutant by Zn (II)-curcumin enhances cell death [20] . In conclusion, CHIP's ability in degrading aggregating mutant p53 in hypoxia as well as under nutrient starvation has implications in developing therapeutic protocols for hypoxic tumor regression (Fig. 11) . Earlier, we had demonstrated the role of CHIP as a molecular chaperone in stabilizing wild-type p53 [47] followed by further demonstration that it could regress hypoxic tumors [48] . The ability of CHIP-mediated autophagic degradation of aggregating mutant p53 in hypoxia to induce cell death may have a therapeutic potential that needs further elaboration. Future work would explore the role of CHIP-mediated autophagic degradation of mutant p53 for regression of hypoxic tumors. 
Materials and methods
Immunoprecipitation
Immunoprecipitation was performed as described with a few modifications [29] . Briefly, cells were harvested 30 h post-transfection and lysed in NP-40 buffer (50 mM Tris/ HCl, pH 7.4, 150 mM NaCl, 1% NP-40, supplemented with a cocktail of protease inhibitor) at 4°C for 30 min. After centrifugation, the pellet was discarded and the supernatant was transferred to fresh tubes. About 1 mg of whole-cell lysate was incubated with 1.0 lg of anti-myc antibodies and incubated with rotation for 3 h at 4°C; 25 lL of 50% v/v protein A-agarose beads was added to the lysate, and a further incubation of 2 h at 4°C with rotation was performed. Beads were washed four to five times with NP-40 buffer. The immunocomplex was released by boiling the beads in the presence of SDS loading dye. Samples were analyzed by western blotting.
Western blot
Protein samples were resolved by SDS/PAGE and then transferred to nitrocellulose membrane using the wet transfer system (Bio-Rad, Hercules, CA, USA). Following transfer, blocking was done by incubating the membrane in blocking buffer (PBS, 0.1% Tween-20 and 5% skimmed milk) for 1 h at room temperature. Subsequently, the membrane was incubated with primary antibodies (1 : 2500) diluted in PBS with 1% BSA and 0.05% Tween-20 for 2-3 h followed by washing thrice (10 min each) with washing buffer. The membrane was then incubated with secondary antibodies (1 : 10 000) conjugated to polyhorseradish peroxidase for 1 h. After subsequent washing, the blot was developed with ECL TM (Millipore) western blotting detection reagents. GENESNAP/GENETOOLS software (Syngene, Frederick, MD, USA) was used to quantitate the band density of the blot.
Confocal microscopy
Cells were grown on coverslips and transfected with GFP-LC3. For visualization, cells were fixed with 4% paraformaldehyde for 20 min at room temperature. After washing with PBS, a coverslip was mounted on a glass slide using 2.5% Dibenzocyclooctyne in glycerol (90%) and visualized under a confocal microscope (Olympus Opto systems India pvt. Ltd, New Delhi, India). Excitation was done using an FITC filter to visualize GFP-LC3.
Flow cytometry
Cell death was determined using PI staining followed by flow cytometry; 1 9 10 5 cells were seeded. After completion of the required treatment, cells were harvested by trypsinization, washed with PBS and finally resuspended in 500 lL PBS with 50 lg mL À1 PI. Cells were incubated for 20 min in the dark at room temperature and subsequently transferred on ice. Cell death as a factor of PI fluorescence intensity was analyzed using a flow cytometer (Beckman Coulter, Brea, CA, USA). Data analysis was carried out using FLOJO software.
In vivo ubiquitination assay
An in vivo ubiquitination assay was performed as described [62] . 
Real-time PCR
Real-time PCR was performed as described [29] . Briefly, quantitative PCRs were performed on an ABI 7000, using SYBR-Green Master Mix (Thermo Fisher Scientific), ABI PRISM 96-well optical reaction plates, and ABI PRISM TM optical adhesive plate sealers. All reactions were completed in triplicate. Each 20 lL PCR contained 0.02-0.1 lg cDNA, 29 SYBR-Green Master Mix, and primers diluted to a final concentration of 0.5 lM. The following cycling parameters were used: 50°C for 10 min and then 95°C for 10 min. This was followed by 40 cycles of 95°C for 10 s and a combined annealing/extension temperature of 60°C for 2 min. During each cycle of the PCR, the fluorescence emitted by the binding of SYBR-Green dye to the doublestranded DNA produced in the reaction was measured. To confirm the specificity of the reactions, dissociation curves were constructed for each primer pair at 0. 
Statistical analysis
Data are reported as the means AE standard error of threeindependent experiments. Comparisons between two groups were carried out using Student's two-tailed t test. Comparisons between multiple groups were performed by one-way ANOVA with Bonferroni post hoc correction. All statistical tests were carried out using PRISM version 5.03 (GraphPad Software, La Jolla, CA, USA), statistics software. P < 0.05 was accepted as significant.
